Results
1
-
1
of
1
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors
,
Cancer Chemotherapy and Pharmacology
[DOI: 10.1007/s00280-011-1565-4]